You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The reissued EUA expands the types of samples that may be used with the Broad Institute's PCR-based SARS-CoV-2 test, which was first authorized in July.
For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.
The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
The test is designed to save resources by testing for the four viruses in one test using single nasopharyngeal, oropharyngeal, or nasal swab samples.
The reissued Emergency Use Authorization from the US Food and Drug Administration also permits the test's use in asymptomatic individuals, the firm said.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
Wren Laboratories and P23 Labs received revised EUAs that allow their previously authorized tests to now be used with new specimen types.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.
The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.
The revenue increase was driven by significant growth in the conglomerate's life sciences segment.
The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.
Researchers showed benefit from chemotherapy in patients classified as high risk by the test, independent of their EGFR mutation status.
The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.
The firms previously received CE mark for a COVID-19 test on the BD Max system in March.
The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.
For the three months ended Sept. 30, the Belgian molecular diagnostic firm's revenues fell to $4.5 million from $4.7 million in Q3 2019.
The firm's variety of COVID-19 molecular and immunoassay test offerings offset declines in the point-of-care segment.
For the three months ended June 30, the firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.
The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.
The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.
A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.
In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.